The aim was to compare the accuracy of the Dexcom G4 Platinum continuous glucose monitor (CGM) sensor inserted on the upper arm and the abdomen in adults. Fourteen adults with type 1 diabetes wore two CGMs, one placed on the upper arm and one placed on the abdomen. Three in-clinic visits of 5 h with YSI (2300 STAT, Yellow Springs Instrument) measurements as comparator were performed. Each visit was followed by 4 days with seven-point self-monitoring of blood glucose (SMBG) in free-living conditions. Accuracy analyses on the paired CGM-YSI and CGM-SMBG measurements of the two CGM sensors were performed. Using YSI as comparator, the overall Mean Absolute Relative Difference (MARD) for the CGM was 12.3% and CGM was 12.0%. The percentage of the CGM measurements in zone A of Clarke error grid analysis for the CGM was 85.6% and CGM was 86.0%. The hypoglycemia sensitivity for the CGM and CGM was 69.3%. Using SMBG as comparator, the overall MARD for the CGM was 12.5% and CGM was 12.0%. The percentage of the CGM measurements in zone A for the CGM was 84.1% and the CGM was 85.0%. The hypoglycemia sensitivity for the CGM was 60.0% and the CGM was 71.1%. All the -values from the comparisons between the accuracy of CGM and CGM were >0.05. The accuracy of a Dexcom G4 Platinum CGM sensor placed on the upper arm was not different from the accuracy of the sensor placed on the abdomen in adults with type 1 diabetes.

Download full-text PDF

Source
http://dx.doi.org/10.1089/dia.2019.0014DOI Listing

Publication Analysis

Top Keywords

cgm
19
upper arm
16
continuous glucose
8
accuracy dexcom
8
dexcom platinum
8
cgm sensor
8
arm abdomen
8
abdomen adults
8
adults type
8
type diabetes
8

Similar Publications

Background: Low back pain (LBP) is the leading cause of disability worldwide. Contrary to clinical guidelines, opioids are frequently prescribed early in the management of LBP in primary care, leading to potential harm and downstream healthcare costs. The objective of this study was to model the one-year impacts of strategies that reduce opioid prescribing for low back pain (LBP) in primary care on healthcare costs and overdose deaths Australia-wide and explore the potential for such strategies to be cost-neutral.

View Article and Find Full Text PDF

Aims: This study assessed real-world glycaemic outcomes associated with the use of Dexcom ONE in adults with suboptimally controlled diabetes.

Methods: In this single-site prospective study, adults with type 1 (T1D) or type 2 diabetes (T2D) taking two or more insulin injections per day initiated Dexcom ONE CGM use and attended follow-up data collection visits after 3 and 6 months. During the study, participants received usual diabetes care.

View Article and Find Full Text PDF

The implanted Eversense Continuous Glucose Monitoring (CGM) System transitioned from 90- to 180- to 365-day durations marketed today. This report summarizes the 365-day clinical study. ENHANCE was a prospective, multicenter study evaluating the accuracy and safety of the Eversense 365 CGM system through 1 year in adults with diabetes.

View Article and Find Full Text PDF

Impact of time in tight range on all-cause and cardiovascular mortality in type 2 diabetes: A prospective cohort study.

Diabetes Obes Metab

January 2025

Department of Endocrinology and Metabolism, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai Clinical Center for Diabetes, Shanghai Diabetes Institute, Shanghai Key Laboratory of Diabetes Mellitus, Shanghai, China.

Aims: Currently, there is a lack of evidence regarding time in tight range (TITR) and long-term adverse outcomes. We aimed to investigate the association between TITR and the risk of all-cause and cardiovascular mortality among patients with type 2 diabetes.

Materials And Methods: A total of 6061 patients with type 2 diabetes were prospectively recruited in a single centre.

View Article and Find Full Text PDF

Aims: The aim of this study was to assess postprandial glycaemic outcomes using automated insulin delivery with faster acting insulin aspart (FIA) or standard insulin aspart (SIA) over 4 weeks in youth (aged 10-18 years) with type 1 diabetes.

Materials And Methods: We undertook a secondary analysis of postprandial glycaemic outcomes from a double-blind, randomised, crossover study comparing FIA to SIA using an investigational version of MiniMed™ 780G. Endpoints included postprandial time in tight range (70-140 mg/dL; TITR), postprandial glucose excursions and peak glucose, and incremental area under curve (iAUC).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!